Member Info for Moorscloud

Interesting thoughts HFH though with all going on for Hemo at the moment - as JHFH made clear earlier - wondering if Vlad really has the time to be moving CDX forward as well, brilliant though that would be.

JHFH - while we just sit at keyboards waiting to see dreams come true... A bit shaming really but go Vlad and Hemo!

Seems every chance HFH especially when you compare Hemo's position in mid-September last year to how close we are now.

Sp seems to be pondering that too BBB

JHFH / HFH - thanks, just the answers was hoping for.

Would $200,000-300,000 be seen as a typical price for such a treatment or put it out of the range of the NHS etc?

Sorry BBB but you're being a feeder. Just box / ignore their dribbles and they disappear: there is so much more in Hemo's current position to discuss and revel in.

Nice follow up for your post yesterday Bline :)

3 great posts today HFH - please re-post at regular intervals tomorrow :)

In a desperate attempt to get away from the pumpky show, what makes you say that Bline? L O N G answer please!

"International Patients: "Medical tourists" who may travel to Estonia to access the therapy, likely paying through private insurance or out-of-pocket" giving the whole world access to Hemo's HG-CT-1 = brilliant move by Vlad and Estonia.

You've been suckered in again JHFH :) How about instead you use your knowledge and experience to explore Hemo's evident ongoing progress in the light of GHD's post on Gilead - that should wind up pumpky.

"New G-rex CAR-T manufacturing demonstrated by Penn State researcher and Hemo Saba Ghassemi." What is the link between Hemo and Saba Ghassemi?

QED pumpky - P1 lives on, a year after treatment.

No comment pumpky?

Anyone else feel pumpky is here to try to drag down sentiment? First Patient anniversary (max 8 days), Made transfer completion, P4 treatment, first child treatment - all imminent. Worth the wait.

"Dose escalation may not therefore meaningfully change the outcome". If so would this have a significant financial effect on the amount of treatment needed per person?

Someone very sensibly transferring into an ISA?

And based on the fact that it is First Patient's historic one year anniversary in less that 7 working days.

Given 3 patients already treated and alive, and the Made transfer nearly complete, and paediatrics permitted, and taking £500m / £1bn to be share prices of around £70 / £140 - ie 7 to 14 times the current sp - would hardly be surprising if a few more investors began to see the value of being here. Very glad to be in already, even if it has been a bumpy 3 years.